ACTON, Mass.--(

马萨诸塞州阿克顿--(

BUSINESS WIRE

商业热线

)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in

)--Insulet Corporation（纳斯达克：PODD）（Insulet或该公司），全球领先

tubeless insulin pump

无管胰岛素泵

technology with its Omnipod

Omnipod技术

®

®

brand of products, today announced the Omnipod 5 Automated Insulin Delivery System is now commercially available in five more countries—Italy, Denmark, Finland, Norway, and Sweden.

今天宣布，Omnipod 5自动胰岛素输送系统现已在另外五个国家（意大利、丹麦、芬兰、挪威和瑞典）上市。

Omnipod 5 is now available with both Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring (CGM) sensor compatibility. Indicated for individuals aged two years and older with type 1 diabetes, Omnipod 5 is the first and only tubeless automated insulin delivery (AID) system integrated with both leading CGM sensor brands..

Omnipod 5现在可与雅培的FreeStyle Libre 2 Plus和Dexcom G6连续血糖监测（CGM）传感器兼容。Omnipod 5适用于2岁及以上的1型糖尿病患者，是第一个也是唯一一个与两个领先的CGM传感器品牌集成的无管自动胰岛素输送（AID）系统。。

“We are excited to bring our flagship Omnipod 5 AID System to more people across Europe,” said Patrick Crannell, Insulet Senior Vice President and International General Manager. “Following our successful launches of Omnipod 5 in the U.K., Germany, Netherlands, and France, today’s announcement marks another significant step forward to help improve the lives of people with diabetes around the world.”.

Insulat高级副总裁兼国际总经理帕特里克·克兰内尔（PatrickCrannell）表示：“我们很高兴将旗舰Omnipod 5援助系统带给欧洲更多的人。”。“继我们在英国、德国、荷兰和法国成功推出Omnipod 5之后，今天的宣布标志着在帮助改善世界各地糖尿病患者生活方面又迈出了重要的一步。”。

Omnipod is recognized as the number one insulin pump for new pump users in Europe

Omnipod被公认为欧洲新泵用户的首选胰岛素泵

1

1

. Omnipod 5 is also the number one prescribed AID system in the U.S.

Omnipod 5也是美国排名第一的规定援助系统。

2

2

and the first tubeless, waterproof

第一个是无内胎防水的

3

3

AID system with proactive glucose control designed to deliver exceptional ease of use. It was first introduced in the U.S. in 2022, integrated with Dexcom G6, and has demonstrated strong clinical results with real world evidence including lower A1c and improved time in range, while maintaining low time in hypoglycemia..

具有主动血糖控制功能的AID系统，旨在提供卓越的易用性。它于2022年首次在美国引入，并与Dexcom G6整合，并通过现实世界的证据证明了强大的临床效果，包括降低A1c和改善范围内的时间，同时保持低血糖的低时间。。

4,5,6

4,5,6

'I can’t wait to get my Omnipod 5 so I can think less about diabetes,” said Lina, a 45-year-old resident of Sweden who has lived with type 1 diabetes for over 20 years. “I had to inject insulin multiple times per day for many years, but I have also been using a tubed insulin pump. Now that Omnipod 5 is available, I am excited to see what difference a tubeless and waterproof AID system will make when doing sports, wearing nice dresses, and skiing.

“我迫不及待地想得到我的Omnipod 5，这样我就可以少考虑糖尿病了，”45岁的瑞典居民丽娜说，她患有1型糖尿病已经20多年了。“多年来，我每天都要多次注射胰岛素，但我也一直在使用管状胰岛素泵。现在Omnipod 5可用了，我很高兴看到无管防水辅助系统在运动、穿着漂亮的连衣裙和滑雪时会产生什么样的变化。

My worry and stress that comes with managing this chronic condition will hopefully lessen, and my active life with diabetes may become simpler.”.

我管理这种慢性病带来的担忧和压力有望减轻，我患糖尿病的积极生活可能会变得更简单。”。

Sensor integration with Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 allows many users to benefit from Omnipod 5 with their sensor of choice. It also gives prescribers more flexibility when recommending a sensor for their patients, making it fast and easy to start AID therapy with Omnipod 5.

传感器与雅培的FreeStyle Libre 2 Plus和Dexcom G6集成，使许多用户可以通过选择的传感器从Omnipod 5中受益。它还为处方者在为患者推荐传感器时提供了更大的灵活性，从而可以快速轻松地使用Omnipod 5开始辅助治疗。

“Omnipod 5 with two sensor choices is going to change lives for people living with type 1 diabetes in Italy and throughout the Nordics. The significant benefits of Omnipod 5, which is transforming diabetes therapy already in other countries, is beyond exciting and welcomed news for so many people with type 1 diabetes who require daily insulin to live,” said Dr.

“具有两个传感器选择的Omnipod 5将改变意大利和整个北欧1型糖尿病患者的生活。Omnipod 5的显着益处正在改变其他国家已经存在的糖尿病治疗方法，对于如此多需要每日胰岛素才能生存的1型糖尿病患者来说，这是一个令人兴奋和受欢迎的消息，”博士说。

Peter Adolfsson, a Senior Physician, MD and pediatrician at the Högsbo Hospital in Sweden..

PeterAdolfsson是瑞典Högsbo医院的高级医师、医学博士和儿科医生。。

To learn more or to get started, visit the

要了解更多信息或开始，请访问

Omnipod website

Omnipod网站

.

.

1

1

Omnipod was the most frequently chosen pump in the past year among people new to an insulin pump in a survey conducted by dQ&A across Germany, Italy, France, United Kingdom, Spain, Netherlands, Sweden. N=3646; 1H'24: P.47 (August 2024).

dQ＆a在德国、意大利、法国、英国、西班牙、荷兰、瑞典进行的一项调查显示，Omnipod是去年新使用胰岛素泵的人群中最常选择的泵。N=3646；24年1月：第47页（2024年8月）。

2

2

USA 2023, Data on file.

美国2023，数据存档。

3

3

The Pod has an IP28 rating for up to 7.6 meters (25 feet) for 60 minutes. The Omnipod

吊舱防护等级为IP28，最高可达7.6米（25英尺），持续60分钟。全足类动物

®

®

5 controller is not waterproof. The Dexcom G6 sensor and transmitter are water-resistant and may be submerged under 2.4 meters (8 feet) of water for up to 24 hours without failure when properly installed. The FreeStyle Libre 2 Plus sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes..

5控制器不防水。Dexcom G6传感器和变送器是防水的，如果安装正确，可以在2.4米（8英尺）的水下浸泡24小时而不会出现故障。FreeStyle Libre 2 Plus传感器在高达1米（3英尺）的水中具有防水性能。。。

4

4

Sherr JL, et al. Diabetes Care (2022). Study in 80 people with type 1 diabetes (T1D) aged 2 - 5.9 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode.

Sherr JL等人，《糖尿病护理》（2022）。。

5

5

Brown et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 - 70 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode.

Brown等人，《糖尿病护理》（2021）。这项研究对240名6-70岁的T1D患者进行了为期两周的标准糖尿病治疗，然后在自动模式下使用Omnipod 5进行了三个月的研究。

6

6

Forlenza GP et al. Diabetes Technology & Therapeutics (2024). Real-World Evidence of Omnipod 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes.

Forlenza GP等人，《糖尿病技术与治疗》（2024）。。

About Insulet Corporation:

关于Islet Corporation：

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods.

总部位于马萨诸塞州的Insulet Corporation（NASDAQ:PODD）是一家创新型医疗器械公司，致力于通过其Omnipod产品平台简化糖尿病和其他疾病患者的生活。Omnipod胰岛素管理系统为传统的胰岛素输送方法提供了独特的替代方案。

With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S.

无管一次性吊舱设计简单，可穿戴，无需查看或操作针头，可提供长达三天的不间断胰岛素输送。Insulat的旗舰创新产品Omnipod 5自动胰岛素输送系统与连续血糖监测仪集成，无需每天多次注射即可管理血糖，无需手指，并且可以通过美国兼容的个人智能手机进行控制。

or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit .

或通过Omnipod 5控制器。Insulat还利用其Pod的独特设计，定制其Omnipod技术平台，用于在其他治疗领域输送非胰岛素皮下药物。有关更多信息，请访问。

Insulet.com

Insulet.com

or

或

omnipod.com

omnipod.com

.

.

©2025 Insulet Corporation. Omnipod and Podder are registered trademarks of Insulet Corporation. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. Dexcom is a registered trademark of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners..

©2025岛屿公司。Omnipod和Podder是Insulet Corporation的注册商标。保留所有权利。传感器外壳、FreeStyle、Libre和相关品牌标志是雅培的标志，并经许可使用。Dexcom是Dexcom，Inc.的注册商标，经许可使用。所有其他商标均为其各自所有者的财产。。